Myanmar Antirheumatic Drugs Market was valued at US$718.219 million in 2020 and is projected to grow during the forecast period.
The significant prevalence of overweight and obesity in Myanmar is causing a rise in the number of people suffering from arthritis which, in turn, is driving the demand for antirheumatic drugs in the country. The growing ageing population in Myanmar, although at a slow pace, will also boost the market growth of antirheumatic drugs in the country to some extent during the forecast period. According to the latest census report, the number of older people aged 65 years and above in Myanmar is projected to triple in the next 30 years. The high prevalence of malaria in Myanmar is also a driving factor for the antirheumatic drugs market. This country is one of the malaria-endemic countries, accounting for almost 10 percent of all the malaria cases in the South-East Asia region. Even though the country has made progress in reducing malaria incidence by 84 percent from 2012 to 2018, more than 76,000 malaria cases and 19 deaths due to malaria were reported in 2018.
Myanmar's antirheumatic drugs market has been segmented based on the type of disease, type of molecule, and sales channel. By type of disease, the market has been segmented as osteoarthritis, rheumatoid arthritis, gout, lupus, and others. By type of molecule, the Myanmar antirheumatic drugs market has been classified into pharmaceuticals and biopharmaceuticals. The market segmentation has also been done by sales channel as prescription and over-the-counter (OTC).
The significant prevalence of overweight and obesity in Myanmar is causing a rise in the number of people suffering from arthritis which, in turn, is driving the demand for antirheumatic drugs in the country. The growing ageing population in Myanmar, although at a slow pace, will also boost the market growth of antirheumatic drugs in the country to some extent during the forecast period. According to the latest census report, the number of older people aged 65 years and above in Myanmar is projected to triple in the next 30 years. The high prevalence of malaria in Myanmar is also a driving factor for the antirheumatic drugs market. This country is one of the malaria-endemic countries, accounting for almost 10 percent of all the malaria cases in the South-East Asia region. Even though the country has made progress in reducing malaria incidence by 84 percent from 2012 to 2018, more than 76,000 malaria cases and 19 deaths due to malaria were reported in 2018.
Myanmar's antirheumatic drugs market has been segmented based on the type of disease, type of molecule, and sales channel. By type of disease, the market has been segmented as osteoarthritis, rheumatoid arthritis, gout, lupus, and others. By type of molecule, the Myanmar antirheumatic drugs market has been classified into pharmaceuticals and biopharmaceuticals. The market segmentation has also been done by sales channel as prescription and over-the-counter (OTC).
COVID-19 SCENARIO
Because of the lockdown, a few procedures are considered urgent, but many have been rescheduled. COVID-19 had a negative influence on the rheumatic illnesses sector because of the widespread postponement as hospital visits plummeted and the drugs were also not available as when required.Segmentation
By Type of Disease
- Osteoarthritis
- Rheumatoid Arthritis
- Gout
- Lupus
By Type of Molecule
- Pharmaceuticals
- Biopharmaceuticals
By Type
- Prescription
- Over-The-Counter (OTC)
Table of Contents
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Dynamics
5. Myanmar Antirheumatic Drug Market Analysis, By Type of Disease
6. Myanmar Antirheumatic Drug Market Analysis, By Type of Molecule
7. Myanmar Antirheumatic Drug Market Analysis, By Type
8. Competitive Environment and Analysis
9. Company Profiles
Companies Mentioned
- Sun Pharmaceutical Industries Ltd.
- Incepta Pharmaceuticals Ltd.
- BPI (Insein)
Methodology
LOADING...
